Refractory Medulloblastoma Recruiting Phase 2 Trials for Olaparib (DB09074)

IndicationStatusPhase
DBCOND0105102 (Refractory Medulloblastoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03155620Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Screening
NCT03233204Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)Treatment